Nanotechnology Now - Press Release: Nano Interface Technology expands application

Home > Press > Nano Interface Technology expands application

Abstract:
Nano Interface Technology (NITI) expands application of its platform technology to solve the problem of the drug-coated stent using nanohydroxyapatite coating technology. The recently recognized problem with the drug-coated stents "late stent thrombosis" can be solved using NITI's nanohydroxyapatite coating technology. The drug-eluting stent has been extremely successful in reducing restenosis from the 20-30% range to single digits. But the growing evidence suggests that drug-eluting stents may be susceptible to an event known as "late stent thrombosis", where blood-clotting on the stent can occur one or more years post-stent, leading to higher mortality. The main reason for late stent thrombosis is lack of endothelization of the stent. The presence of polymer and/or collagen in the coating delays and/or prevents endothelization of the stent surface.

Nano Interface Technology expands application

Lorton, VA | Posted on December 8th, 2006

"Bone consists of 70% of hydroxyapatite which helps tissue to bind with it," stated C. P. Singh, Ph.D., President & CEO of NITI. "The presence of nanohydroxyapatite coatings on the stent can provide excellent opportunity for early endothelization of the stent. The hydroxyapatite and drug coated stent can be fine tuned to prevent restenosis and "late stent thrombosis". The purity of hydroxyapatite in the coatings is very important because the dissolution of hydroxyapatite from the dental implants within weeks is well reported due to the impurity in the coatings." In the past, a Dental Implant Company faced lawsuit for the early dissolution of the coatings. NITI's platform technology provides high purity nano-size coatings of the hydroxyapatite as compared to a competitor's hydroxyapatite-coated stents.

####

About Nano Interface Technology
About Nano Interface Technology, Inc. (www.nanointerfacetech.com) NITI develops and markets cutting–edge technologies designed to make biomedical devices more effective. The Company develops enabling technologies for implanted medical systems such as orthopedic implants, dental implants and stents which have total market of $20 billion.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors including, but not limited to: the success of NITI’s coating technology, the successful implementation of NITI’s product development programs; the acceptance of NITI’s products by the market; competition, timing of projects and trends in future performance.

For more information, please click here

Contacts:
Maya Sinha, VP
Telephone: (703)339-2929

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: